Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility Gene (BRCA)-mutated or homologous recombination-deficient tumor cells can induce “synthetic lethality”, which targets two DNA re...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xuan, Li, Weihua, Li, Xiaoying, Bai, Huimin, Zhang, Zhenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519338/
https://www.ncbi.nlm.nih.gov/pubmed/31191001
http://dx.doi.org/10.2147/CMAR.S200524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519338/
https://www.ncbi.nlm.nih.gov/pubmed/31191001
http://dx.doi.org/10.2147/CMAR.S200524

Ejemplares similares